(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
In8bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast INAB's revenue for 2027 to be $650,882,692, with the lowest INAB revenue forecast at $650,882,692, and the highest INAB revenue forecast at $650,882,692. On average, 1 Wall Street analysts forecast INAB's revenue for 2028 to be $6,400,752,762, with the lowest INAB revenue forecast at $6,400,752,762, and the highest INAB revenue forecast at $6,400,752,762.
In 2029, INAB is forecast to generate $11,754,892,656 in revenue, with the lowest revenue forecast at $11,754,892,656 and the highest revenue forecast at $11,754,892,656.